Collegium Pharmaceutical, Inc.
S&P 600
$22.75
-0.74%
Delayed · cached 15 min
Peer comparison
| Company | Price↕ | Market Cap↕ | P/E↕ | P/B↕ | ROE %↕ | ROCE %↕ | Div yield %↕ | Valuation |
|---|---|---|---|---|---|---|---|---|
| Lilly (Eli) | $ 1,115.70 | $994.92B | 37.45 | 29.36 | 60.92 | 24.04 | 0.58 | Above FV |
| Johnson & Johnson | $ 265.58 | $640.02B | 30.77 | 7.53 | 31.54 | 22.17 | 1.97 | Above FV |
| Merck & Co. | $ 143.93 | $355.10B | 115.14 | 8.47 | 43.53 | 20.76 | 2.29 | Above FV |
| Pfizer | $ 27.72 | $157.99B | 36.47 | 1.85 | 9.12 | 4.58 | 6.22 | Above FV |
| Bristol Myers Squibb | $ 63.64 | $130.00B | 14.02 | 5.83 | 31.61 | 14.53 | 3.94 | Above FV |
| Zoetis | $ 72.97 | $30.15B | 11.90 | 9.31 | 84.91 | 26.16 | 2.83 | Above FV |
| Viatris | $ 16.51 | $18.96B | -5.50 | 1.31 | 1,748.71 | -9.53 | 2.93 | — |
| Jazz Pharmaceuticals | $ 245.80 | $15.96B | 16.84 | 3.32 | -7.42 | -4.87 | 0.00 | — |
| Corcept Therapeutics Incorporated | $ 112.79 | $12.19B | 250.64 | 17.25 | 14.12 | 6.20 | 0.00 | Above FV |
| Elanco | $ 23.17 | $11.57B | -49.30 | 1.76 | -3.52 | -1.87 | 0.00 | — |
| Alkermes plc | $ 45.97 | $7.71B | 120.97 | 4.26 | 13.36 | 6.60 | 0.00 | Above FV |
| PTC Therapeutics, Inc. | $ 66.06 | $5.51B | 8.49 | -33.28 | -412.82 | 37.99 | 0.00 | — |
Price, market cap, P/E, P/B and dividend yield reflect the live quote (delayed, cached 15 min); ROE/ROCE from reported financials. The highlighted row is the current company. Click a column header to sort. Educational data only.
How to read the peer comparison
This table places the company beside others in the same industry on a few common measures. Comparison adds context that a single company's numbers cannot give on their own.
- Valuation multiples like P/E and P/B are most meaningful within the same industry, because different industries naturally trade at different levels. Comparing a company only to its peers is more useful than to the whole market.
- Return measures (ROE, ROCE) show how efficiently each company turns capital into profit. A company well ahead of or behind its peers here is worth understanding.
- No single column decides anything. A beginner reads the row across — valuation, returns, and size together — and treats the highlighted current company as one data point among its peers.
- Use the sortable headers to rank peers on any measure, but remember that "cheaper" or "higher" on one metric is a starting question, not an answer.
Educational only — not a recommendation to buy, sell, or hold any security.